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Background: Major depressive disorder (MDD) is a complex psychiatric condition with
different subtypes and etiologies. Exposure to adverse childhood experiences (ACE) is
an important risk factor for the development of MDD later in life. Evidence suggests that
pro-inflammatory processes may convey this risk as both MDD and ACE have been
related to increased levels of inflammation. In the present study, we aimed to disentangle
the effects of MDD and ACE on inflammation levels.
Methods: Markers of inflammation (plasma interleukin(IL)-6 and high sensitive C-reactive
protein (hsCRP) concentrations, white blood cell (WBC) count and a composite
inflammation score (CIS) combining all three) were assessed in 23 MDD patients with
ACE, 23 MDD patients without ACE, 21 healthy participants with ACE, and 21 healthy
participants without ACE (mean age: 35 ± 11 (SD) years). None of the patients and
participants was taking psychotropic medication. ACE was assessed with the Early
Trauma Inventory (ETI) and was defined as moderate to severe exposure to sexual or
physical abuse.
Results: Group differences in the different inflammatory measures were observed. MDD
patients with ACE showed significantly higher IL-6 concentrations (p = 0.018), higher
WBC counts (p = 0.003) and increased general inflammation levels as indicated by the
CIS (p = 0.003) compared to healthy controls. In contrast, MDD patients without ACE
displayed similar inflammation levels to the control group (p = 0.93).
Conclusion: We observed elevated inflammation in MDD patients with a history of ACE,
which could indicate a subtype of “inflammatory depression”. Accordingly, MDD patients
with ACE might potentially benefit from anti-inflammatory therapies.
Keywords: acute-phase protein, childhood adversity, childhood maltreatment, depression, inflammation, pro-
inflammatory cytokine
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INTRODUCTION
Major depressive disorder (MDD) is a frequent and heterogenic
disorder and despite numerous studies performed over the
last decades, there are still inconsistencies in clinical findings
regarding the pathological mechanisms contributing to the
development of MDD (1). Therefore, greater understanding
of the biological processes and pathways underlying the
pathophysiology of depression is of key importance for the
development of early interventions and personalized therapies.
Adverse childhood experiences (ACE) have been shown to
predispose to the development of MDD later in life (2, 3) and
in addition induce greater risk for acquiring several somatic
conditions, including cardiovascular disease (CVD) (3). A large
body of evidence suggests that ACE is linked to a chronic
pro-inflammatory state in adulthood (4–6). Alterations in the
dynamics of the neuroendocrine stress response likely contribute
to the manifestation of a pro-inflammatory immune phenotype
in these individuals (7). It has been suggested that stressors
occurring early in life can be biologically embedded through
epigenetic modifications in stress-related genes (8) and program
the immune system to become hyper-responsive in response to
challenge with diminished sensitivity to the inhibitory effect of
glucocorticoids (9).
Chronic inflammation is characterized by elevated levels of
pro-inflammatory cytokines, acute phase proteins, and increases
in white blood cell (WBC) numbers (10–12). Several studies
reported higher circulating levels of inflammatory mediators,
such as the pro-inflammatory cytokine IL-6 and the acute phase-
protein C-reactive protein (CRP) (4, 5), and increased WBC
counts (13, 14) in adults exposed to early adversity. Because
chronic inflammation is associated with both ACE and several
physical and psychiatric conditions, including MDD (15–18), it
has been proposed as a key mechanism through which severe
stress exposure during childhood can influence health outcomes
throughout the lifespan (6, 19). This notion is further supported
by the observation that increased activation of pro-inflammatory
pathways (reflected by increased circulating levels of CRP and IL-
6) precedes the development of depressive symptoms (17), and
by studies that report that inflammation is more pronounced in a
subgroup of MDD patients that are exposed to ACE (20–23).
The overall goal of the present study was to replicate
previous findings regarding associations between ACE, MDD
and inflammation, and to further disentangle the effects of
MDD and ACE on inflammation using a well-controlled, full
factorial design including four carefully diagnosed groups of
healthy participants and MDD patients with and without a
history of ACE. None of the patients and participants was taking
psychotropic medication. We hypothesized accumulative effects
of MDD and ACE on inflammation levels.
MATERIAL AND METHODS
Participants
Patients and healthy participants were recruited by public
postings and from our specialized affective disorder unit at
the Department of Psychiatry and Psychotherapy, Campus
Benjamin Franklin, Charité -Universitätsmedizin Berlin. All
participants provided written informed consent. Healthy
participants and outpatients received monetary compensation
for their participation. The study was approved by the local
ethical committee.
Depressed patients were included if they fulfilled criteria for
MDD as assessed with the Structured Clinical Interview for
DSM-IV axis I (SCID-I) (24) to validate psychiatric diagnoses.
In addition, current depressive symptoms were captured by the
Montgomery Asberg Depression Rating Scale (MADRS) (25, 26)
and the Beck Depression Inventory (BDI) (27).
ACE was assessed by using a semi-structured interview, the
Early Trauma Inventory (ETI) (28, 29), and was defined as
repeated physical or sexual abuse at least once a month over one
year or more before the age of 18.
In the MDD groups, schizophrenia, schizoaffective disorder,
bipolar disorder, depressive disorder with psychotic features,
dementia, eating disorders, panic disorder, alcohol or drug
dependence led to exclusion. Healthy participants with and
without ACE were free of any current mental disorder. Further
exclusion criteria for all participants were CNS relevant diseases,
neurological diseases, severe somatic diseases, diabetes type 1 and
2, steroid diseases, hypertonia, current infections, pregnancy and
the intake of psychotropic medication. Physical health criteria
were checked by physical examination, clinical interview and a
complete blood count (CBC).
The study sample comprised 23 MDD patients with
ACE (MDD+/ACE+), 23 MDD patients without ACE
(MDD+/ACE–), 21 participants with ACE but no current,
or lifetime MDD (MDD–/ACE+) and 21 participants with
no current or lifetime MDD and no childhood adversity
(MDD–/ACE–, healthy comparison group).
Study Protocol
All patients and participants underwent one study visit including
psychiatric and medical diagnostic by physical examination,
blood sampling and clinical interviews including SCID-I and
MADRS as well as assessment of ACE using the ETI.
Afterwards they completed a MDD related questionnaire (BDI).
Blood samples were sent immediately to the laboratory of
the Institute of Medical Psychology, Campus Mitte, Charité–
Universitätsmedizin Berlin, Germany, and to the Labor Berlin–
Charité Vivantes GmbH, Berlin, Germany, for further analyses.
Inflammatory Measures
Plasma IL-6 concentrations were analyzed using a commercially
available high sensitivity ELISA kit (eBioscience), according to
the manufacturer’s instructions. The limit of detection was 0.007
pg/ml. The intra- and inter-assay coefficients of variability for
plasma IL-6measurements were 10 and 12%, respectively. Plasma
hsCRP concentrations were analyzed using a commercially
available Instant ELISA kit (eBioscience), according to the
manufacturer’s instructions. The limit of detection was 3 pg/ml.
The intra- and inter-assay coefficients of variability for plasma
hsCRP measurements were 6 and 8%, respectively. WBC counts
were obtained from a standard clinical complete blood count
panel using a Sysmex XN 1000 (Sysmex).
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Statistics
General linear models and Chi2 tests were used to compare
groups concerning demographics and clinical data (see Table 1).
Post hoc tests (Bonferroni) were conducted when applicable. IL-
6 and hsCRP measures were first log transformed to normalize
distributions. Since IL-6 and hsCRP concentrations and WBC
count are established measures of pro-inflammatory activity,
represent three biologically related components of inflammation
[i.e., (a) pro-inflammatory cytokines (b) acute phase proteins
and (c) increasedWBC numbers], and inter-correlated with each
other (all r’s >0.2), we combined these measures into a single
composite measure. Principal-component analysis identified
one single factor, the composite inflammation score (CIS),
accounting for 48% of the variance in analyte determinations. A
common factor takes full advantage of the predictive values of
the three measures, while minimizing measurement errors of the
single components (21).
General linear models were used to compare groups regarding
inflammatory measures. In order to investigate the groups effects
on inflammatory measures in more detail, and because we
expected the lowest inflammation levels in the control group, we
studied a priori defined contrasts between the controls and the
three study groups.
Many potential cofounders were excluded by design (see
above). However, additional adjusted analysis included covariates
that differed significantly between the four groups (i.e., BMI and
smoking see Table 1).
Data analysis was performed using the SPSS statistical
software (SPSS 23.0, Inc., Chicago, IL, USA). The significance
level was set at p< 0.05 for all applied analysis.
Missing Data
Complete blood counts were missing for 8 individuals (4
MDD+/ACE+, 2 MDD+/ACE–, 1 MDD–/ACE+ and 1 MDD–
/ACE–). For IL-6, a measurement was missing for 1MDD patient
without ACE (MDD+/ACE–). General linear models indicated
there were no group differences regarding the number of missing
biological measurements (p= 0.42).
RESULTS
Sample Characteristics
Table 1 summarizes group demographics and clinical
characteristics. In accordance with our recruitment, MDD
patients and healthy participant with ACE (MDD+/ACE+,
MDD–/ACE+) had significantly higher total ETI scores
compared to the MDD patients without ACE (MDD+/ACE–)
and the control group (MDD–/ACE–). MDD patients with
and without ACE did not differ in depression severity and
both groups had higher depression scores compared to healthy
individuals with and without ACE. MDD patients with ACE
had a higher BMI compared to MDD patients without ACE and
smoked more than healthy controls. No group differences were
observed in age, sex and educational level.
Inflammatory Measures
As presented in Table 2, we identified significant group effects on
IL-6 [F(3, 83) = 3.32, p = 0.024, η
2 = 0.11], CRP concentration
[F(3, 84) = 3.10, p = 0.031, η
2 = 0.10] and WBC count
[F(3, 76) = 3.44, p = 0.021, η
2 = 0.12]. To investigate these
effects in more detail, we studied a priori defined contrasts
between controls and the different study groups (see Table 3).
We observed significantly higher IL-6 concentrations (p= 0.018)
and WBC counts (p = 0.003) in MDD patients with ACE
compared to healthy controls, also after controlling for BMI
and smoking (IL-6, p = 0.044; WBC count, p = 0.048). CRP
levels were significantly higher in healthy individuals with ACE
(p = 0.031). However, this effect was no longer significant after
controlling for BMI and smoking (p = 0.052). Untransformed
and unadjusted mean group values for IL-6, hsCRP and WBC
counts are presented in Figures 1A–C.
There was a significant group effect on the CIS [F(3, 75) = 4.76,
p =0.004, η2 = 0.16, Table 2]. Contrasts between the controls
and the different study groups showed that inflammation
levels tended to be increased in healthy participants with ACE
(p = 0.073, Table 3) and were significantly higher in MDD
patients with ACE compared to healthy controls (p = 0.003,
Table 3), also after controlling for BMI and smoking (p = 0.034,
Table 3). Unadjusted mean group CIS values are depicted in
Figure 1D.
DISCUSSION
With the present study we aimed to disentangle the effects of
MDD and ACE on alterations in levels of inflammation by using
well-controlled, defined and discrete groups of adults with and
without a history of ACE and an MDD diagnosis. Confirming
our hypothesis, we observed the highest inflammation levels in
MDD patients with a history of ACE. These results replicate
prior research showing that inflammation is elevated in a
subgroup of MDD patients exposed to ACE (21). Our results
are also in line with previous studies reporting that elevations in
inflammatory measures observed inMDD patients are associated
with childhood trauma (22, 23, 30). Another study comparing
cytokine levels between healthy controls and MDD patients with
and without a history of ACE found the highest levels of 13
different cytokines in the ACE exposed MDD patients (31).
However, in contrast to our findings, no increases in plasma
levels of IL-6 were observed in this subgroup of MDD patients.
A possible explanation for this discrepancy could be the use of
different assay methodology.
Group differences were not completely homogenous
regarding the different inflammatory measures that we assessed.
While IL-6 concentrations and WBC counts were elevated in
MDD patients with ACE, higher CRP concentrations were seen
in healthy individuals exposed to ACE compared to healthy
controls. This last finding is supported by a recent meta-analysis
suggesting that the association between childhood trauma and
inflammatory measures, including CRP, is not moderated by the
presence of a psychiatric diagnosis (5). However, our finding
that CRP is increased in healthy individuals exposed to ACE
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TABLE 1 | Demographic and clinical characteristics of healthy participants and depressed patients without ACE (MDD–/ACE–, MDD+/ACE–) and healthy participants











Age (SD) 33.90 (9.77) 32.61 (11.74) 34.05 (10.53) 38.09 (11.36) p = 0.36
Sex (m/f) 8/13 5/18 6/15 9/14 p = 0.55
BMI (SD) 23.23 (3.56)a,b 21.49 (2.87)a 23.79 (3.14)a,b 25.05 (2.93)b p = 0.003
Smoking (y/n) 4/17 a 5/18 a 7/14 a,b 14/9 b p = 0.012
Educational level (%)
Lower/Intermediate 23.8% 21.7% 28.6% 47.8% p = 0.21
Upper Secondary School 76.2% 78.3% 71.4% 52.2%
DEPRESSIVE SYMPTOMS
BDI (SD) 1.05 (1.56)a 25.41 (8.96)b 4.64 (4.75)a 26.81 (8.62)b p < 0.001
MADRS score (SD) 0.62 (0.81)a 28.26 (5.71)b 1.67 (1.83) a 27.41 (8.01)b p < 0.001
ADVERSE CHILDHOOD EXPERIENCES
ETI sum score (SD) 12.67 (21.13) a 195.39 (205.48)a 619.62 (371.74)b 752.09 (482.57)b p < 0.001
a,bGroups with values that do not share a superscript within the same line of text are significantly different from each other. ACE, Adverse childhood experiences; BMI, Body mass index;
BDI, Becks Depression Index; ETI, Early Trauma Interview; GLM, General linear model; MADRS, Montgomery Asberg Depression Rating Scale; MDD, Major depressive disorder; SD,
Standard deviation.
TABLE 2 | Mean values of the inflammatory measures of healthy participants and depressed patients without ACE (MDD–/ACE–, MDD+/ACE–) and healthy participants
and depressed patients with ACE (MDD–/ACE+, MDD+/ACE+).
MDD–/ACE– MDD+/ACE– MDD–/ACE+ MDD+/ACE+ GLM
IL-6 (Ln) pg/ml (SE) −1.28 (0.25) −1.44 (0.30) −1.12 (0.29) −0.43 (0.14) F (3, 83) = 3.32
p = 0.024
hsCRP (Ln) mg/L (SE) −1.96 (0.22) −2.12 (0.21) −1.20 (0.29) −1.49 (0.23) F (3, 84) = 3.10
p = 0.031
WBC count 109/L (SE) 6.01 (0.27) 6.52 (0.53) 6.97 (0.53) 8.09 (0.50) F (3, 76) = 3.44
p = 0.021
CIS (SE) −0.36 (0.16) −0.39 (0.23) 0.18 (0.24) 0.57 (0.20) F (3, 75) = 4.76
p = 0.004
ACE, Adverse childhood experiences; Composite inflammation score; GLM, General linear model, MDD, Major depressive disorder; SE, Standard error; WBC, White blood cell.
was no longer significant after adjusting for BMI and smoking.
As previously reported by others, unhealthy lifestyle factors like
increased BMI and smoking are associated with ACE (32) and
have been shown to have an effect on inflammation (33, 34).
Therefore, these lifestyle factors could have contributed to the
observed elevations in CRP concentrations.
Altogether, the data presented here support the hypothesis
that ACEmight be a risk factor for developing aMDD later in life,
and that this risk is partly mediated by increases in activation of
pro-inflammatory pathways (19). In line with this, inflammation
levels did not differ between MDD patients without ACE
and healthy controls, suggesting that biological mechanisms,
other than inflammation, might play a more prominent role
in the pathogenesis of depression in these patients. Although
previous research has shown increased inflammatory measures
in depression (15, 17, 18), in most studies the effects of ACE have
not been taken into account.
ACE is not only a risk factor for the development of
depression. Also other psychiatric disorders, such as post-
traumatic stress-disorder (PTSD), anxiety disorders, and bipolar
disorder have been associated with a history of ACE (35,
36) and are as well related to increased inflammation (37,
38). However, until now, only few studies systematically
investigated the separate and interactive effects of disease status
and a history of ACE on inflammation (39–41). Therefore,
future research should attempt to further identify the role of
ACE in activating inflammatory pathways in these psychiatric
conditions.
Findings from this study are limited by the use of a
cross sectional design and the relatively modest sample
size, which might have led to insufficient power. Also our
study sample included relatively more female than male
participants, indicating that our results might be impacted by
gender bias. However, the groups did not differ significantly
regarding the female to male ratio. In addition, the number of
immune parameters that we assessed was limited, and future
studies should include additional measures of acute-phase
proteins, cytokines, and immune cell characteristics in order
to gain better understanding of the biological processes and
pathways underlying the inflammation-related pathophysiology
of depression in patients with and without a history
of ACE.
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TABLE 3 | Mean differences in inflammatory measures between each of the three study groups (MDD+/ACE–, MDD–/ACE+ and MDD+/ACE+) and control group
(MDD–/ACE–) before (unadjusted) and after adjusting for BMI and smoking.
MDD–/ACE– MDD+/ACE– MDD–/ACE+ MDD+/ACE+
IL-6 (Ln) pg/ml



















































ACE, Adverse childhood experiences; CI, Confidence interval; CIS, Composite inflammation score; MDD, Major depressive disorder; WBC, White blood cell. *indicates significant
difference compared to the control group, p-value < 0.05; **p-value < 0.01.
FIGURE 1 | Untransformed and unadjusted mean group values for (A) Il-6, (B) hsCRP, (C) WBC count and (D) the unadjusted mean group CIS (±SE). *p-value <
0.05, **p-value < 0.01 in comparison to the control group (MDD–/ACE–). ACE, Adverse childhood experiences; CIS, Composite inflammation score; MDD, Major
depressive disorder; WBC, White blood cell.
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Our study has several strengths. The study sample consisted of
four carefully diagnosed groups which allowed us to disentangle
the effects of MDD and ACE on inflammation. Furthermore,
none of the patients and participants was taking psychotropic
medications. All patients and participants received detailed
diagnostics and a physical examination. Our findings of increased
levels of inflammation in MDD patients (and to a lesser extent
in healthy individuals) exposed to ACE, in this rather young
study sample further emphasize the clinical importance of our
results, since elevated inflammation is a risk factor implied
in the development of somatic disorders like CVD (3, 42).
Moreover, the pro-inflammatory state observed in depression
also has consequences for treatment success, since patients with
elevated inflammation are less likely to respond to conventional
antidepressants (43, 44).
In summary, in this well-controlled study, we replicated
findings from prior research suggesting accumulative effects
of MDD and ACE on a more pro-inflammatory state, while
inflammation levels did not differ betweenMDDpatients without
ACE and healthy controls. These findings suggest that a subgroup
of MDD patients with a history of ACE might benefit from an
anti-inflammatory intervention.
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